Antiandrogenic activity of norgestimate in a human androgen-dependent stable-transfected cell line

References

• Lucky A W. Hormonal correlates of acne and hirsutism. Am J Med 1995; 98(Suppl 1A)89S–94S
   Google Scholar
• Burkman R T, Jr. The role of oral contraceptives in the treatment of hyperandrogenic disorders. Am J Med 1995; 98(Suppl 1A)S130–S136
   Google Scholar
• Lucky A W, Henderson T A, Olson W H, Robisch D M, Lebwohl M, Swinyer L J. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997; 37: 746–754
   PubMed Web of Science ®Google Scholar
• Redmond G P, Olson W H, Lippman J S, Kafrissen M E, Jones T M, Jorizzo J L. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 1997; 89: 615–622
   PubMed Web of Science ®Google Scholar
• Olson W H, Lippman J S, Robisch D M. The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris. Int J Fertil 1998; 6: 286–290
   Google Scholar
• Janaud A, Rouffy J, Upmalis D, Dain M P. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel. Acta Obstet Gynecol Scand Suppl 1992; 156: 33–38
   PubMedGoogle Scholar
• Burkman R, Jr, Kafrissen M, Olson W, Osterman J. Lipid and carbohydrate effects of a new triphasic oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand Suppl 1992; 156: 5–8
   Google Scholar
• Gobinet J, Poujol N, Sultan C. Molecular action of androgens. Mol Cell Endocrinol 2002; 198: 15–24
   PubMed Web of Science ®Google Scholar
• Phillips A, Hahn D W, Klimek S, McGuire J L. A comparison of the potencies and activities of progestogens used in contraceptives. Contraception 1993; 36: 181–192
   Google Scholar
• Phillips A. The selectivity of a new progestin. Acta Obstet Gynecol Scand Suppl 1990; 152: 21–24
   PubMedGoogle Scholar
• Hammond G L, Abrams L S, Creasy G W, Natarajan J, Allen J G, Siiteri P K. Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties. Contraception 2003; 67: 93–99
   PubMed Web of Science ®Google Scholar
• Terouanne B, Tahiri B, Georget V, Belon C, Poujol N, Avances C, Orio F, Jr, Balaguer P, Sultan C. A stable prostatic bioluminescent cell line to investigate androgen and antiandrogen effects. Mol Cell Endocrinol 2000; 160: 39–49
   PubMed Web of Science ®Google Scholar
• Terouanne B, Paris F, Servant N, Georget V, Sultan C. Evidence that chlormadinone acetate exhibits antiandrogenic activity in androgen-dependent cell line. Mol Cell Endocinol 2002; 198: 143–147
   PubMed Web of Science ®Google Scholar
• Nirde P, Terouanne B, Gallais N, Sultan C, Auzou G. Antimineralocorticoid 11β-substituted spirolactones exhibit androgen receptor agonistic activity: a structure function study. Mol Pharmacol 2001; 59: 1307–1313
   PubMed Web of Science ®Google Scholar
• Georget V, Lobaccaro J M, Terouanne B, Mangeat P, Nicolas J C, Sultan C. Trafficking of the androgen receptor in living cells with fused green fluorescent protein-androgen receptor. Mol Cell Endocrinol 1997; 129: 17–26
   PubMed Web of Science ®Google Scholar
• Avances C, Georget V, Terouanne B, Orio F, Cussenot O, Mottet N, Costa P, Sultan C. Human prostatic cell line PNT1A, a useful tool for studying androgen receptor transcriptional activity and its differential subnuclear localization in the presence of androgens and antiandrogens. Mol Cell Endocrinol 2001; 184: 13–24
   PubMedGoogle Scholar
• Chapdelaine A, Desmarais J, Derman R J. Clinical evidence of the minimal androgenic activity of norgestimate. Int J Fertil 1989; 34: 347–352
   PubMedGoogle Scholar
• Juchem M, Pollow K, Elger W, Hoffmann G, Mobus V. Receptor binding of norgestimate – a new orally active synthetic progestational compound. Contraception 1993; 47: 283–294
   Google Scholar
• London R S, Chapdelaine A, Upmalis D, Olson W, Smith J. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. Acta Obstet Gynecol Scand Suppl 1992; 156: 9–14
   Google Scholar
• Andolsek K. Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent. Acta Obstet Gynecol Scand Suppl 1992; 156: 22–26
   Google Scholar
• Rabe T, Kowald A, Ortmann J, Rehberger-Schneider S. Inhibition of skin 5α-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol 2000; 14: 223–230
   PubMed Web of Science ®Google Scholar
• Labrie C, Cusan L, Plante M, Lapointe S, Labrie F. Analysis of the androgenic activity of synthetic ‘progestins’ currently used for the treatment of prostate cancer. J Steroid Biochem 1987; 28: 379–384
   PubMedGoogle Scholar
• Plante M, Lapointe S, Labrie F. Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice. J Steroid Biochem 1988; 31: 61–64
   PubMedGoogle Scholar
• Luthy I A, Begin D J, Labrie F. Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem 1988; 31: 845–852
   PubMedGoogle Scholar
• Poulin R, Baker D, Poirier D, Labrie F. Multiple actions of synthetic ‘progestins’ on the growth of ZR-75-1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids. Breast Cancer Res Treat 1991; 17: 197–210
   Google Scholar
• Sator P G, Schmidt J B, Hönigsmann H. Clinical evidence of the endocrinological influence of a triphasic oral contraceptive containing norgestimate and ethinyl estradiol in treating women with acne vulgaris. Dermatology 2003; 206: 241–248
   PubMed Web of Science ®Google Scholar